Table 1.
Demographic and clinical data and scores of the five CHAQ versions of patients and healthy controls.
| JIA | Healthy | p-value | |
|---|---|---|---|
| n | 89 | 22 | |
| Age (years) | 11.9 (2.7) | 12.0 (2.7) | 0.67 |
| Sex (m/f) | 19/70 | 12/10 | |
| Diagnosis (n =) | |||
| PA | 40 | ||
| SA | 10 | ||
| PO | 17 | ||
| EO | 9 | ||
| OL | 6 | ||
| Missing | 7 | ||
| Disease duration (years) | 5.4 (3.6) | ||
| Disease activity (n = (%)) | |||
| Active | 38 (43) | ||
| Remission | 49 (55) | ||
| Missing | 2 (2) | ||
| Medication (n = (%)) | |||
| None | 14 (16) | ||
| NSAID | 43 (48) | ||
| MTX | 46 (52) | ||
| Prednisolone | 9 (10) | ||
| Biologicals | 24 (27) | ||
| Joint Involvement (median (IQR)) | 10 (10-30) | ||
| VAS Pain | 2.7 (0-9.5) | ||
| VAS GA | 2.5 (0-10) | ||
| CHAQ30orig | 0.38 (0-2.13) |
Scores for VAS and CHAQ are presented as median and range. Values for age and disease duration are presented as mean and standard deviation.
Polyarthritis; SA, Systemic Arthritis; PO, Persistent Oligoarthritis; EO, Extended Oligoarthritis; OL, Oligoartrhitis; VAS GA: Visual analogue scale global assessment of overall wellbeing. Joint involvement: percentage of joints affected by JIA.